These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32009210)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.
    McCarthy MW
    Clin Pharmacokinet; 2020 May; 59(5):567-573. PubMed ID: 32009210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
    Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR; Rybak JM; Claeys KC
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
    Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
    J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
    J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
    Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
    Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
    Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications.
    Ghazi IM; El Nekidy WS; Sood A; Dulku A; Patel R; Patel K; Li P
    Clin Ther; 2020 Mar; 42(3):475-485. PubMed ID: 32139175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA
    Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
    Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
    Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
    [No Abstract]   [Full Text] [Related]  

  • 19. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
    Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres.
    Shields RK; Yücel E; Turzhitsky V; Merchant S; Min JS; Watanabe AH
    J Glob Antimicrob Resist; 2024 Jun; 37():190-194. PubMed ID: 38588973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.